



Immune Responses in Brain Cancer

Guest Editor:

Dr. Theo Kraus

Institute of Pathology, University
Hospital Salzburg, Paracelsus
Medical University, Müllner
Hauptstraße 48, A-5020 Salzburg,
Austria

Deadline for manuscript
submissions:

closed (15 September 2022)

Message from the Guest Editor

Dear Colleagues,

The interactions between tumor and immune response are of emerging interest in understanding both tumor biology and therapy failure. Thereby, there is a broad range of potential interactions between tumor cells and immune cells. In contrast to other organs, the brain represents a special situation: it is a site of immune privilege. However, this very traditional view has changed in recent years. Recent studies emphasize that there are complex immunological interactions between the brain and other organs. These novel developments may be of significant importance for advanced brain tumor therapy. Thereby, glioma represent the most frequent brain tumors of adults, with glioblastoma being the most malignant brain tumor, showing a devastating outcome. Despite intensive research, there are still no curative therapies available for glioma. In this Special Issue, we aim to highlight the importance of the immune response in brain tumors with recent studies on the interaction of the immune system and brain tumors to pave the way for novel immune-modulating therapies in brain tumors.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)